Matthew Galsky, MD
img_Matthew Galsky
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Urology
Are you a patient?
Specialties
Cancer (Oncology)

MD, Tufts University

Residency, Internal Medicine, Beth Israel Deaconess Medical Center

Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center

Certifications

American Board of Internal Medicine

2003

American Society of Clinical Oncology Merit Award

1998

Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)

1998

Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)

1997

Alpha Omega Alpha Honor Society

Publications

Selected Publications

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj. Cancer Discovery

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Siamak Daneshmand, Ashish M. Kamat, Neal D. Shore, Joshua J. Meeks, Matthew D. Galsky, Joseph M. Jacob, Michiel S. van der Heijden, Stephen B. Williams, Thomas Powles, Sam S. Chang, James W.F. Catto, Sarah P. Psutka, Félix Guerrero-Ramos, Evanguelos Xylinas, Makito Miyake, Giuseppe Simone, Karen Daniel, Hussein Sweiti, Christopher Cutie, Andrea Necchi. Urologic Oncology: Seminars and Original Investigations

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Matthew D. Galsky, Karen A. Autio, Christopher R. Cabanski, Kristopher Wentzel, Julie N. Graff, Terence W. Friedlander, Timothy R. Howes, Kristin M. Shotts, Julie Densmore, Marko Spasic, Diane M. Da Silva, Richard O. Chen, Jennifer Lata, Jeffrey Skolnik, Tibor Keler, Michael J. Yellin, Theresa M. LaVallee, Justin Fairchild, Silvia Boffo, Jill O’Donnell-Tormey, Ute Dugan, Nina Bhardwaj, Sumit K. Subudhi, Lawrence Fong. Clinical Cancer Research

View All Publications

Immune Checkpoint Blockade: A New Era in Cancer Treatment

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Galsky during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Aktis
  • AbbVie, Inc.
  • AstraZeneca
  • Seattle Genetics
  • Gilead Sciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.